search
EADV Congress
Trends
- 1EADV Congress 2026: Day 2 Roundup of Key Headlines▼EADV Congress 2026: Day 2 Recap—6 Headlines to Know
The European Academy of Dermatology and Venereology's 2026 congress continued into its second day, with a recap highlighting six headline developments from the meeting. Coverage focuses on the key research presentations, clinical updates, and announcements emerging from the event, giving dermatology specialists a digest of the most notable news so far.
- 2EADV Congress 2026 Opens With Six Key Headlines▼EADV Congress 2026: Day 1 Recap — 6 Headlines to Know
The European Academy of Dermatology and Venereology has begun its 2026 Congress, with day one yielding six headline developments in dermatology and venereology. Coverage highlights new clinical findings and treatment updates presented at the meeting, which brings together skin-health specialists from around the world. Attendees and medical media are summarising the most notable announcements as the congress continues.
- 3New Rezpegaldesleukin Data Shows Durable Results at EADV 2026▼New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New clinical data for rezpegaldesleukin, an immune-regulating drug candidate, show long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis. The findings are being presented at the EADV Congress 2026, Europe's major dermatology meeting. The data support the treatment's potential for these chronic inflammatory skin conditions, where maintaining improvement over time remains a key challenge for patients and physicians.
- 4Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy▼New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.
- 5New Biomarker Data on Rezpegaldesleukin Presented at EADV Congress 2026●New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.
- 6CytoAgents Unveils New Preclinical Data on CTO1681●CytoAgents Presents New Preclinical CTO1681 Data at the 2026 EADV Congress
CytoAgents presented new preclinical data on its investigational compound CTO1681 at the 2026 EADV Congress, the European Academy of Dermatology and Venereology's annual meeting. The company says the findings support the drug candidate's development potential in dermatology. Details of the data and the indication being targeted have not been broadly reported, and the announcement is drawing attention from investors and dermatology specialists following the congress presentation.